Browse the evidence

The proportion of participants discontinuing treatment for any reason was lower with semaglutide (13.5%) compared to liraglutide (27.6%).

Semaglutide may lead to better treatment adherence compared to liraglutide.

The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class, with gastrointestinal events being the most common adverse effects.

Practitioners should be aware of the gastrointestinal side effects associated with orforglipron, particularly during dose escalation.

Energy intake was greater during the ultra-processed diet by 508±106 kcal/d (p=0.0001).

Practitioners should be aware that ultra-processed diets can lead to higher calorie consumption.

The combination of Semaglutide and VLCD provoked greater improvements in pancreatic beta-cell function than VLCD alone.

Combining Semaglutide with VLCD may enhance pancreatic function in T2D management.

Free-living total daily energy expenditure (TDEE) increased by ~4% in the 20 KKW group.

Increased exercise can enhance daily energy expenditure, which may aid in weight management.

Leptin, GDF-15, and FGF-21 decreased, whereas adiponectin increased after weight loss.

Monitoring these biomarkers can provide insights into the effects of weight loss on metabolic health.

Higher dose levels of GLP-1RAs may have better effects on weight loss.

Consideration of dose levels may optimize weight loss outcomes with GLP-1RAs.

Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with bariatric metabolic surgery (BMS) (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).

Tirzepatide may be a safer option for reducing mortality in obese patients compared to surgical interventions.

Tirzepatide reduced the risk of major adverse cardiovascular events (MACEs) (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).

Tirzepatide may help reduce cardiovascular risks in obese patients.

Tirzepatide reduced the risk of major adverse kidney events (MAKEs) (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).

Tirzepatide may be beneficial for kidney health in obese patients.

The SASI group had a total weight loss of 37.0% compared to 29.7% in the SG group at 12 months after surgery.

Practitioners may consider SASI for enhanced weight loss in severely obese patients.

The SASI group achieved a lower BMI of 23.4 ± 2.6 kg/m² compared to 24.6 ± 2.9 kg/m² in the SG group at 12 months.

Lower BMI in the SASI group suggests it may be more effective for weight management.

Total energy expenditure (TEE) decreased significantly with caloric restriction.

Practitioners should be aware that caloric restriction leads to a significant decrease in total energy expenditure.

The 12-month difference in VAT loss between diets attenuated to 5.5 cm².

Long-term adherence to dietary interventions may yield diminishing returns in VAT loss.

Semaglutide and tirzepatide resolve metabolic dysfunction-associated steatohepatitis (MASH) in 41% and 53% of patients, respectively, without worsening fibrosis after 52-72 weeks.

These medications can significantly improve liver health in adults with MASH.

Phentermine/topiramate ER treatment improved glucose regulation, lipid profiles, and decreased blood pressure.

The treatment may enhance metabolic health in obese patients.

Lean mass constituted 25%–39% of total weight lost with incretin agonists: semaglutide (35.2%), tirzepatide (25.4%), and liraglutide (26.8%).

Incretin therapies can lead to significant lean mass loss during weight reduction.

Lifestyle interventions showed comparable proportional lean mass loss (26.2%) to incretin therapies (p = 0.42 for comparison).

Lifestyle interventions can be as effective as incretin therapies in preserving lean mass during weight loss.

The intervention resulted in greater decreases in fasting total cholesterol (−13.2±25.0 mg/dl) compared to control (−2.4±24.2 mg/dl, p=0.0423).

Implementing dietary changes in worksite programs can improve cholesterol levels.

Efsubaglutide Alfa showed a preferable tolerability and safety profile.

Efsubaglutide Alfa may be a safer option for weight management compared to other treatments.

NAFLD is a risk factor for atherosclerotic cardiovascular disease.

Clinicians should consider NAFLD when assessing cardiovascular risk in patients.

Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.

Semaglutide may be an effective treatment option for improving liver histology in patients with MASH.

In the 15-mg tirzepatide group, 62% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 53 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

Weight gain during adulthood was associated with significantly increased risk of major chronic diseases.

Practitioners should counsel patients on the risks associated with weight gain throughout adulthood.